Caldera Therapeutics

Caldera Therapeutics is a Boston-based biotechnology company dedicated to developing innovative therapeutic solutions for inflammatory bowel disease and other immunologic conditions, focusing on its bispecific antibody product, CLD-423

calderatx.com

Biotech & Life Sciences

Sector

Seed

Stage

Biotechnology

Model

01Company Overview

02Backed By2 investors

vPvenBio Partners→OFOmega Funds→

Is this your company? Claim your profile

Startup Intelligence by F4F4 Research Engine

Recent Activity

FROM Atlas Venture

Portfolio company Caldera Therapeutics agreed to a reverse merger with Synlogic and a $278M concurrent private placement to reach Nasdaq as CALD.

EXIT·businesswire.com

JUL 29, 2026

FROM Omega Funds

Launched Caldera Therapeutics with $112.5M financing and first subjects dosed in a Phase 1 trial for a bispecific antibody targeting inflammatory bowel disease.